HANSOH PHARMA - VOLUNTARY ANNOUNCEMENT - THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093 IN COMBINATION WITH ADEBRELIMAB

Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

THE NMPA HAS GRANTED BREAKTHROUGH-THERAPY-DESIGNATED DRUG FOR B7-H3-TARGETED ANTIBODY-DRUG CONJUGATE HS-20093

IN COMBINATION WITH ADEBRELIMAB

The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that, on April 16, 2026, the Group's self-developed B7-H3-targeted antibody-drug conjugate (ADC) HS-20093 for injection in combination with adebrelimab has obtained approval to be included as a Breakthrough-Therapy-Designated Drug by the National Medical Products Administration (NMPA) of China, with the proposed indication for locally advanced or metastatic non-squamous non-small cell lung cancer without actionable genomic alterations that has progressed or relapsed after platinum-based chemotherapy.

By Order of the Board

Hansoh Pharmaceutical Group Company Limited Zhong Huijuan

Chairlady

Hong Kong, April 16, 2026